Table 6 Clinical trials for targeting the PI3k signalling in breast cancer
From: Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway
Clinical trial | Drug/Treatment | Study type and phase | Enrollment | Study starts and completion year | Status |
|---|---|---|---|---|---|
NCT02506556 | BYl719 | II (Interventional) | 36 | 2015–2021 | Completed |
NCT01513356 | BKM120 | I (Interventional) | 20 | 2012–2014 | Completed |
NCT00499603 | Paclitaxel 5-Fluorouracil Epirubicin Cyclophosphamide RAD001 | II (Interventional) | 62 | 2007–2017 | Unknown |
NCT03962647 | Letrozole 2-Week Ketogenic Diet | I (Interventional) | 31 | 2019–2025 | Active (Not recruiting) |
NCT01339442 | BKM120 Fulvestrant Biopsy | I (Interventional) | 31 | 2011–2016 | Completed |
NCT02058381 | BYL719 BKM120 | I (Interventional) | 40 | 2014–2018 | Completed |
NCT01363232 | BKM120 MEK162 | I (Interventional) | 89 | 2011–2017 | Completed |
NCT01337765 | BEZ235 MEK162 | I (Interventional) | 29 | 2011–2013 | Completed |
NCT01155453 | BKM120 GSK1120212 | I (Interventional) | 113 | 2010–2014 | Completed |
NCT01920061 | Gedatolisib` Docetaxel Cisplatin Dacomitinib | I (Interventional) | 110 | 2013–2020 | Completed |
NCT01980277 | LY2780301 paclitaxel | I, II (Interventional) | 68 | 2014–2018 | Terminated |
NCT05810870 | MEN1611 Eribulin | II (Interventional) | 28 | 2023–2027 | Active (Recruiting) |
NCT01501604 | BKM120 | II (Interventional) | 0 | 2012–2013 | Withdrawn |
NCT04108858 | Copanlisib Pertuzumab Trastuzumab | I, II (Interventional) | 2 | 2021–2022 | Terminated |
NCT02069158 | PF-05212384 Paclitaxel Carboplatin | I (Interventional) | 17 | 2014–2019 | Completed |
NCT01298713 | Tamoxifen Everolimus | II (Interventional) | 111 | 2008–2018 | Completed |
NCT04345913 | Biopsy Biospecimen Collection Computed Tomography Copanlisib Hydrochloride Eribulin Mesylate Magnetic Resonance Imaging | I, II (Interventional) | 106 | 2021–2023 | Active (Not recruiting) |
NCT03243331 | Gedatolisib PTK7-ADC | I (Interventional) | 18 | 2018–2020 | Completed |
NCT03765983 | Trastuzumab GDC-0084 | II (Interventional) | 47 | 2019–2025 | Active (Recruiting) |